Effect of ultralow doses of antibodies to S-100 protein in animals with impaired cognitive function and disturbed emotional and neurological status under conditions of experimental Alzheimer disease

T A Voronina; M V Belopol'skaya; I A Kheyfets; Yu L Dugina; S A Sergeeva; O I Epshtein

doi:10.1007/s10517-010-0757-y

Effect of ultralow doses of antibodies to S-100 protein in animals with impaired cognitive function and disturbed emotional and neurological status under conditions of experimental Alzheimer disease

Bull Exp Biol Med. 2009 Sep;148(3):533-5. doi: 10.1007/s10517-010-0757-y.

[Article in English, Russian]

Authors

T A Voronina¹, M V Belopol'skaya, I A Kheyfets, Yu L Dugina, S A Sergeeva, O I Epshtein

Affiliation

¹ Materia Medica Holding Research-and-Production Company, Moscow.

PMID: 20396733
DOI: 10.1007/s10517-010-0757-y

Abstract

Course administration of ultralow doses of antibodies to S-100 protein restores cognitive functions and neurological status, improves emotional state, and reduces anxiety in animals with modeled Alzheimer disease based on cholinergic system deficiency caused by subchronic treatment with scopolamine.

MeSH terms

Alzheimer Disease / drug therapy*
Alzheimer Disease / pathology
Animals
Antibodies / immunology*
Antibodies / therapeutic use*
Anxiety / drug therapy
Avoidance Learning / drug effects
Cognition / drug effects*
Cognition Disorders / drug therapy
Male
Neuropsychological Tests
Rats
S100 Proteins / immunology*
Scopolamine / therapeutic use

Substances

Antibodies
S100 Proteins
Scopolamine